Current Medical Treatment for Alcohol-Associated Liver Disease

Gao, 2011, Alcoholic liver disease: pathogenesis and new therapeutic targets, Gastroenterology, 141, 1572, 10.1053/j.gastro.2011.09.002

2018, Electronic address: [email protected], European association for the study of the liver. EASL clinical practice guidelines: management of alcohol-related liver disease, J Hepatol, 69, 154, 10.1016/j.jhep.2018.03.018

Crabb, 2020, Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American association for the study of liver diseases, Hepatology, 71, 306, 10.1002/hep.30866

Arab, 2019, Alcohol-related liver disease: clinical practice guidelines by the Latin American association for the study of the liver (ALEH), Ann Hepatol, 18, 518, 10.1016/j.aohep.2019.04.005

Rehm, 2017, The relationship between different dimensions of alcohol use and the burden of disease-an update, Addiction, 112, 968, 10.1111/add.13757

Phillips, 2021, Dietary guidelines for Americans, 2020-2025, Workplace Health & Saf, 69, 395, 10.1177/21650799211026980

Julien, 2021, Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-related liver disease: a modeling study, Hepatology

Rutledge, 2021, COVID-19 aftershocks on alcohol-associated liver disease: an early cross-sectional report from the U.S. Epicenter, Hepatol Commun, 5, 1151, 10.1002/hep4.1706

Moon, 2021, Alcohol-associated liver disease before and after COVID-19-an overview and call for ongoing investigation, Hepatol Commun, 5, 1616, 10.1002/hep4.1747

Mauro, 2020, Telemedicine improves access to Hepatology consultation with high patient satisfaction, J Clin Exp Hepatol, 10, 555, 10.1016/j.jceh.2020.04.017

Simonetto, 2020, Outpatient management of alcohol-related liver disease, Lancet Gastroenterol Hepatol, 5, 485, 10.1016/S2468-1253(19)30415-7

2013

Singal, 2018, ACG clinical guideline: alcoholic liver disease, Am J Gastroenterol, 113, 175, 10.1038/ajg.2017.469

Lackner, 2017, Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease, J Hepatol, 66, 610, 10.1016/j.jhep.2016.11.011

Singal, 2020, Epidemiology and surveillance for hepatocellular carcinoma: new trends, J Hepatol, 72, 250, 10.1016/j.jhep.2019.08.025

Singal, 2018, Prevention and management of alcoholic liver disease, 351

Huynh, 2015, Nutritional care in hospitalized patients with chronic liver disease, World J Gastroenterol, 21, 12835, 10.3748/wjg.v21.i45.12835

Yao, 2018, Dietary interventions in liver cirrhosis, J Clin Gastroenterol, 52, 663, 10.1097/MCG.0000000000001071

Henkel, 2006, Nutritional support in patients with chronic liver disease, Nat Clin Pract Gastroenterol Hepatol, 3, 202, 10.1038/ncpgasthep0443

Merli, 1996, Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi), Hepatology, 23, 1041, 10.1002/hep.510230516

Lochs, 2006, Introductory to the ESPEN guidelines on enteral nutrition: terminology, definitions and general topics, Clin Nutr, 25, 180, 10.1016/j.clnu.2006.02.007

Plauth, 2019, ESPEN guideline on clinical nutrition in liver disease, Clin Nutr, 38, 485, 10.1016/j.clnu.2018.12.022

Tantai, 2021, Effect of sarcopenia on survival in patients with cirrhosis: a systematic review and meta-analysis, J Hepatol

Anand, 2017, Nutrition and muscle in cirrhosis, J Clin Exp Hepatol, 7, 340, 10.1016/j.jceh.2017.11.001

Singal, 2012, Nutrition in alcoholic liver disease, Clin Liver Dis, 16, 805, 10.1016/j.cld.2012.08.009

Bunchorntavakul, 2020, Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis, Aliment Pharmacol Ther, 51, 64, 10.1111/apt.15571

Tandon, 2021, Sarcopenia and frailty in decompensated cirrhosis, J Hepatol, 75, S147, 10.1016/j.jhep.2021.01.025

Cruz-Jentoft, 2019, Sarcopenia: revised European consensus on definition and diagnosis, Age Ageing, 48, 16, 10.1093/ageing/afy169

Lai, 2021, Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American association for the study of liver diseases, Hepatology, 74, 1611, 10.1002/hep.32049

Wu, 2020, Current understanding of the metabolism of micronutrients in chronic alcoholic liver disease, World J Gastroenterol, 26, 4567, 10.3748/wjg.v26.i31.4567

Masalkar, 2005, Oxidative stress and antioxidant status in patients with alcoholic liver disease, Clin Chim Acta, 355, 61, 10.1016/j.cccn.2004.12.012

Hart, 2010, Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies, BMJ, 340, c1240, 10.1136/bmj.c1240

Åberg, 2018, Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population, Hepatology, 67, 2141, 10.1002/hep.29631

Boyle, 2018, The bidirectional impacts of alcohol consumption and the metabolic syndrome: cofactors for progressive fatty liver disease, J Hepatol, 68, 251, 10.1016/j.jhep.2017.11.006

Puri, 2021, Nutrition in chronic liver disease: consensus statement of the Indian national association for study of the liver, J Clin Exp Hepatol, 11, 97, 10.1016/j.jceh.2020.09.003

Wharton, 2020, Obesity in adults: a clinical practice guideline, CMAJ, 192, E875, 10.1503/cmaj.191707

Carias, 2016, Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation, J Gastroenterol Hepatol, 31, 10.1111/jgh.13166

Gallagher, 2005, Adipose tissue in muscle: a novel depot similar in size to visceral adipose tissue, Am J Clin Nutr, 81, 903, 10.1093/ajcn/81.4.903

Bischoff, 2020, ESPEN practical guideline: clinical nutrition in liver disease, Clin Nutr, 39, 3533, 10.1016/j.clnu.2020.09.001

Kondrup, 2003, Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials, Clin Nutr, 22, 321, 10.1016/S0261-5614(02)00214-5

Sorensen, 2008, EuroOOPS: an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome, Clin Nutr, 27, 340, 10.1016/j.clnu.2008.03.012

Wu, 2020, Royal Free Hospital-Nutritional Prioritizing Tool improves the prediction of malnutrition risk outcomes in liver cirrhosis patients compared with Nutritional Risk Screening 2002, Br J Nutr, 124, 1293, 10.1017/S0007114520002366

Borhofen, 2016, The royal free hospital-nutritional prioritizing tool is an independent predictor of deterioration of liver function and survival in cirrhosis, Dig Dis Sci, 61, 1735, 10.1007/s10620-015-4015-z

Tandon, 2017, A practical approach to nutritional screening and assessment in cirrhosis, Hepatology, 65, 1044, 10.1002/hep.29003

Carey, 2019, A north American expert opinion statement on sarcopenia in liver transplantation, Hepatology, 70, 1816, 10.1002/hep.30828

Paris, 2020, Automated body composition analysis of clinically acquired computed tomography scans using neural networks, Clin Nutr, 39, 3049, 10.1016/j.clnu.2020.01.008

Carey, 2017, A multicenter study to define sarcopenia in patients with end-stage liver disease, Liver Transplant, 23, 625, 10.1002/lt.24750

Mitsiopoulos, 1998, Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography, J Appl Physiol, 85, 115, 10.1152/jappl.1998.85.1.115

Tapper, 2015, Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis, Hepatology, 62, 584, 10.1002/hep.27830

Thuluvath, 2018, Karnofsky performance status before and after liver transplantation predicts graft and patient survival, J Hepatol, 69, 818, 10.1016/j.jhep.2018.05.025

Tandon, 2017, A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis, Hepatology, 65, 217, 10.1002/hep.28900

Kalafateli, 2017, Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score, J Cachexia Sarcopenia Muscle, 8, 113, 10.1002/jcsm.12095

Koretz, 2012, Nutritional support for liver disease, Cochrane Database Syst Rev, 5, CD008344

Ney, 2013, Meta-analysis: oral or enteral nutritional supplementation in cirrhosis, Aliment Pharmacol Ther, 37, 672, 10.1111/apt.12252

Moreno, 2016, Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids, Gastroenterology, 150, 903, 10.1053/j.gastro.2015.12.038

Maharshi, 2016, Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial, Clin Gastroenterol Hepatol, 14, 454, 10.1016/j.cgh.2015.09.028

Rivera Irigoin, 2012, [Nutritional support in patients with liver cirrhosis], Gastroenterol Hepatol, 35, 594, 10.1016/j.gastrohep.2012.03.001

Plank, 2008, Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial, Hepatology, 48, 557, 10.1002/hep.22367

Swart, 1989, Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver, BMJ, 299, 1202, 10.1136/bmj.299.6709.1202

Zillikens, 1993, Nocturnal oral glucose supplementation. The effects on protein metabolism in cirrhotic patients and in healthy controls, J Hepatol, 17, 377, 10.1016/S0168-8278(05)80221-1

Tsien, 2012, Late evening snack: exploiting a period of anabolic opportunity in cirrhosis, J Gastroenterol Hepatol, 27, 430, 10.1111/j.1440-1746.2011.06951.x

Yoshida, 1989, Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis, Gastroenterol Jpn, 24, 692, 10.1007/BF02774169

Muto, 2005, Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis, Clin Gastroenterol Hepatol, 3, 705, 10.1016/S1542-3565(05)00017-0

Kawaguchi, 2011, Branched-chain amino acids as pharmacological nutrients in chronic liver disease, Hepatology, 54, 1063, 10.1002/hep.24412

Marchesini, 2003, Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial, Gastroenterology, 124, 1792, 10.1016/S0016-5085(03)00323-8

Manguso, 2005, Effects of an appropriate oral diet on the nutritional status of patients with HCV-related liver cirrhosis: a prospective study, Clin Nutr, 24, 751, 10.1016/j.clnu.2005.02.010

Nielsen, 1995, Long-term oral refeeding of patients with cirrhosis of the liver, Br J Nutr, 74, 557, 10.1079/BJN19950158

Ruiz-Margáin, 2018, Effect of a high-protein, high-fiber diet plus supplementation with branched-chain amino acids on the nutritional status of patients with cirrhosis, Rev Gastroenterol México, 83, 9, 10.1016/j.rgmx.2017.02.005

Horst, 1984, Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial, Hepatology, 4, 279, 10.1002/hep.1840040218

Córdoba, 2004, Normal protein diet for episodic hepatic encephalopathy: results of a randomized study, J Hepatol, 41, 38, 10.1016/j.jhep.2004.03.023

Bémeur, 2015, Reprint of: nutrition in the management of cirrhosis and its neurological complications, J Clin Exp Hepatol, 5, S131, 10.1016/j.jceh.2015.02.004

Matsuoka, 2014, Improvement in the nutritional status and clinical conditions of patients with liver failure using a liver diet combined with a branched chain amino acids-enriched elemental diet, Hepato-Gastroenterology, 61, 1308

Mills, 1983, Assessment of nutritional status and in vivo immune responses in alcoholic liver disease, Am J Clin Nutr, 38, 849, 10.1093/ajcn/38.6.849

Schenker, 1993, Nutritional therapy in alcoholic liver disease, Semin Liver Dis, 13, 196, 10.1055/s-2007-1007349

Lieber, 1991, Alcohol, liver, and nutrition, J Am Coll Nutr, 10, 602, 10.1080/07315724.1991.10718182

Lindor, 1993, Management of osteopenia of liver disease with special emphasis on primary biliary cirrhosis, Semin Liver Dis, 13, 367, 10.1055/s-2007-1007365

Lucidi, 2018, A low muscle mass increases mortality in compensated cirrhotic patients with sepsis, Liver Int, 38, 851, 10.1111/liv.13691

Gluud, 2017, Branched-chain amino acids for people with hepatic encephalopathy, Cochrane Database Syst Rev, 5, CD001939

Sinclair, 2016, Low serum testosterone is associated with adverse outcome in men with cirrhosis independent of the model for end-stage liver disease score, Liver Transplant, 22, 1482, 10.1002/lt.24607

Sinclair, 2016, Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial, J Hepatol, 65, 906, 10.1016/j.jhep.2016.06.007

Harper, 1995, An international perspective on the prevalence of the Wernicke-Korsakoff syndrome, Metab Brain Dis, 10, 17, 10.1007/BF01991779

Torvik, 1991, Wernicke's encephalopathy--prevalence and clinical spectrum, Alcohol Alcohol Suppl, 1, 381

Galvin, 2010, EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy, Eur J Neurol, 17, 1408, 10.1111/j.1468-1331.2010.03153.x

Day, 2013, Thiamine for prevention and treatment of Wernicke-Korsakoff Syndrome in people who abuse alcohol, Cochrane Database Syst Rev, 7, CD004033

Praharaj, 2021, High-dose thiamine strategy in Wernicke-Korsakoff syndrome and related thiamine deficiency conditions associated with alcohol use disorder, Indian J Psychiatr, 63, 121, 10.4103/psychiatry.IndianJPsychiatry_440_20

Ganatra, 2021, Clinical guideline highlights for the hospitalist: 2020 American society of addiction medicine clinical practice guideline on alcohol withdrawal management, J Hosp Med

Latt, 2014, Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders, Intern Med J, 44, 911, 10.1111/imj.12522

Shah, 2019, Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide, Clin Gastroenterol Hepatol, 17, 2320, 10.1016/j.cgh.2019.01.026

Argemi, 2020, Alcoholic-related liver disease: pathogenesis, management and future therapeutic developments, Rev Esp Enferm Dig, 112, 869, 10.17235/reed.2020.7242/2020

Xu, 2021, The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: a diagnostic or screening tool?, J Formos Med Assoc

Asphaug, 2020, Cost-effectiveness of noninvasive screening for alcohol-related liver fibrosis, Hepatology, 71, 2093, 10.1002/hep.30979

Moreno, 2019, Non-invasive diagnosis and biomarkers in alcohol-related liver disease, J Hepatol, 70, 273, 10.1016/j.jhep.2018.11.025

Stickel, 2017, Pathophysiology and management of alcoholic liver disease: update 2016, Gut Liver, 11, 173, 10.5009/gnl16477

Lucey, 2009, Automatically detecting pain using facial actions, Int Conf Affect Comput Intell Interact Workshops, 2009, 1

Crabb, 2016, Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia, Gastroenterology, 150, 785, 10.1053/j.gastro.2016.02.042

Singal, 2013, Model for end-stage liver disease, J Clin Exp Hepatol, 3, 50, 10.1016/j.jceh.2012.11.002

Kamath, 2001, A model to predict survival in patients with end-stage liver disease, Gastroenterology, 120, A76, 10.1016/S0016-5085(01)80377-2

Farnsworth, 2004, Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients, Am J Surg, 188, 580, 10.1016/j.amjsurg.2004.07.034

Arab, 2021, Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: a worldwide study, J Hepatol, 75, 1026, 10.1016/j.jhep.2021.06.019

Srikureja, 2005, MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis, J Hepatol, 42, 700, 10.1016/j.jhep.2004.12.022

Mathurin, 2011, Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data, Gut, 60, 255, 10.1136/gut.2010.224097

Forrest, 2018, Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis, J Hepatol, 68, 511, 10.1016/j.jhep.2017.11.017

Arraez

Atkinson, 2020, In severe alcoholic hepatitis, serum keratin-18 fragments are diagnostic, prognostic, and theragnostic biomarkers, Am J Gastroenterol, 115, 1857, 10.14309/ajg.0000000000000912

Kumar, 2019, Relative adrenal insufficiency in patients with alcoholic hepatitis, J Clin Exp Hepatol, 9, 215, 10.1016/j.jceh.2018.09.002

Altamirano, 2012, Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis, Clin Gastroenterol Hepatol, 10, 65, 10.1016/j.cgh.2011.09.011

Simonetto, 2020, Hepatorenal syndrome: pathophysiology, diagnosis, and management, BMJ, 370, m2687, 10.1136/bmj.m2687

Angeli, 2015, Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites, Gut, 64, 531, 10.1136/gutjnl-2014-308874

Piano, 2013, Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites, J Hepatol, 59, 482, 10.1016/j.jhep.2013.03.039

Martín-Llahí, 2008, Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study, Gastroenterology, 134, 1352, 10.1053/j.gastro.2008.02.024

Facciorusso, 2017, Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis, Lancet Gastroenterol Hepatol, 2, 94, 10.1016/S2468-1253(16)30157-1

Solé, 2018, Hepatorenal syndrome in the era of acute kidney injury, Liver Int, 38, 1891, 10.1111/liv.13893

Ojeda-Yuren, 2021, An integrated review of the hepatorenal syndrome, Ann Hepatol, 22, 100236, 10.1016/j.aohep.2020.07.008

Mookerjee, 2007, Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome, Hepatology, 46, 831, 10.1002/hep.21737

Llopis, 2016, Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease, Gut, 65, 830, 10.1136/gutjnl-2015-310585

Ike, 1990, Genetic analysis of the pAD1 hemolysin/bacteriocin determinant in Enterococcus faecalis: tn917 insertional mutagenesis and cloning, J Bacteriol, 172, 155, 10.1128/jb.172.1.155-163.1990

Duan, 2019, Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease, Nature, 575, 505, 10.1038/s41586-019-1742-x

Vergis, 2017, In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA, Gastroenterology, 152, 1068, 10.1053/j.gastro.2016.12.019

Flamm, 2011, Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence, Therap Adv Gastroenterol, 4, 199, 10.1177/1756283X11401774

Kulkarni, 2021, IDDF2021-ABS-0089 Primary norfloxacin prophylaxis reduces the incidence of infections in severe alcoholic hepatitis-A double-blind, randomized controlled study

Støy, 2021, No effect in alcoholic hepatitis of gut-selective, broad-spectrum antibiotics on bacterial translocation or hepatic and systemic inflammation, Clin Transl Gastroenterol, 12, 10.14309/ctg.0000000000000306

Mathurin, 2000, Exacerbation of alcoholic liver injury by enteral endotoxin in rats, Hepatology, 32, 1008, 10.1053/jhep.2000.19621

Enomoto, 1998, Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin, Gastroenterology, 115, 443, 10.1016/S0016-5085(98)70211-2

Morgan, 1996, The treatment of alcoholic hepatitis, Alcohol Alcohol, 31, 117, 10.1093/oxfordjournals.alcalc.a008123

Szabo, 2012, Innate immunity and alcoholic liver disease, Dig Dis, 30, 55, 10.1159/000341126

Louvet, 2018, Corticosteroids reduce risk of death within 28 Days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials, Gastroenterology, 155, 458, 10.1053/j.gastro.2018.05.011

Altamirano, 2014, A histologic scoring system for prognosis of patients with alcoholic hepatitis, Gastroenterology, 146, 1231, 10.1053/j.gastro.2014.01.018

O'Shea, 2010, Practice guideline committee of the American association for the study of liver diseases and the practice parameters committee of the American college of gastroenterology. Alcoholic liver disease, Hepatology, 51, 307, 10.1002/hep.23258

Pavlov, 2017, Glucocorticosteroids for people with alcoholic hepatitis, Cochrane Database Syst Rev, 11, CD001511

Singal, 2021, Diagnosis and treatment of alcohol-associated liver disease: a review, JAMA, 326, 165, 10.1001/jama.2021.7683

Forrest, 2013, Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial, Trials, 14, 262, 10.1186/1745-6215-14-262

Singal, 2016, Therapeutic strategies for the treatment of alcoholic hepatitis, Semin Liver Dis, 36, 56, 10.1055/s-0036-1571297

Maddrey, 1978, Corticosteroid therapy of alcoholic hepatitis, Gastroenterology, 75, 193, 10.1016/0016-5085(78)90401-8

Blitzer, 1977, Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study, Am J Dig Dis, 22, 477, 10.1007/BF01072499

Lesesne, 1978, Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements, Gastroenterology, 74, 169, 10.1016/0016-5085(78)90790-4

Shumaker, 1978, A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients, Am J Gastroenterol, 69, 443

Depew, 1980, Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy, Gastroenterology, 78, 524, 10.1016/0016-5085(80)90867-7

Theodossi, 1982, Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis, Gut, 23, 75, 10.1136/gut.23.1.75

Carithers, 1989, Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial, Ann Intern Med, 110, 685, 10.7326/0003-4819-110-9-685

Ramond, 1992, A randomized trial of prednisolone in patients with severe alcoholic hepatitis, N Engl J Med, 326, 507, 10.1056/NEJM199202203260802

Cabré, 2000, Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial, Hepatology, 32, 36, 10.1053/jhep.2000.8627

Phillips, 2006, Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial, J Hepatol, 44, 784, 10.1016/j.jhep.2005.11.039

Campra, 1973, Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial, Ann Intern Med, 79, 625, 10.7326/0003-4819-79-5-625

Helman, 1971, Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy, Ann Intern Med, 74, 311, 10.7326/0003-4819-74-3-311

Owens, 2016, Pharmacologic treatment of alcoholic hepatitis: examining outcomes based on disease severity stratification, J Clin Exp Hepatol, 6, 275, 10.1016/j.jceh.2016.07.003

Mendenhall, 1984, Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone, N Engl J Med, 311, 1464, 10.1056/NEJM198412063112302

Thursz, 2015, Prednisolone or pentoxifylline for alcoholic hepatitis, N Engl J Med, 372, 1619, 10.1056/NEJMoa1412278

Singal, 2014, Alcoholic hepatitis: current challenges and future directions, Clin Gastroenterol Hepatol, 12, 555, 10.1016/j.cgh.2013.06.013

Singal, 2011, Alcoholic hepatitis: prognostic models and treatment, Gastroenterol Clin N Am, 40, 611, 10.1016/j.gtc.2011.06.008

Louvet, 2007, The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids, Hepatology, 45, 1348, 10.1002/hep.21607

Garcia Rodríguez, 2001, The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents, Arthritis Res, 3, 98, 10.1186/ar146

Singal, 2012, Hepatitis C virus infection in alcoholic hepatitis: prevalence patterns and impact on in-hospital mortality, Eur J Gastroenterol Hepatol, 24, 1178, 10.1097/MEG.0b013e328355cce0

Segev, 2008, Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials, Liver Transplant, 14, 512, 10.1002/lt.21396

Shoreibah, 2014, Alcoholic hepatitis and concomitant hepatitis C virus infection, World J Gastroenterol, 20, 11929, 10.3748/wjg.v20.i34.11929

Mathurin, 2015, Trends in the management and burden of alcoholic liver disease, J Hepatol, 62, S38, 10.1016/j.jhep.2015.03.006

Louvet, 2009, Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor, Gastroenterology, 137, 541, 10.1053/j.gastro.2009.04.062

Michelena, 2015, Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis, Hepatology, 62, 762, 10.1002/hep.27779

Kwong, 2021, Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease, Transl Gastroenterol Hepatol, 6, 3, 10.21037/tgh.2020.02.18

Tornai, 2020, Emerging medical therapies for severe alcoholic hepatitis, Clin Mol Hepatol, 26, 686, 10.3350/cmh.2020.0145

Smirnova, 2020, Fecal microbiome distinguishes alcohol consumption from alcoholic hepatitis but does not discriminate disease severity, Hepatology, 72, 271, 10.1002/hep.31178

Dong, 2020, A microbial signature identifies advanced fibrosis in patients with chronic liver disease mainly due to NAFLD, Sci Rep, 10, 2771, 10.1038/s41598-020-59535-w

Lang, 2020, Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis, Hepatology, 71, 522, 10.1002/hep.30832

Karakike, 2017, Infections in severe alcoholic hepatitis, Ann Gastroenterol Hepatol, 30, 152

Templeton, 2008, Multilumen central venous catheters increase risk for catheter-related bloodstream infection: prospective surveillance study, Infection, 36, 322, 10.1007/s15010-008-7314-x

Simon, 1988, A randomized controlled study of peripheral parenteral nutrition in moderate and severe alcoholic hepatitis, J Hepatol, 7, 200, 10.1016/S0168-8278(88)80483-5

Kulkarni, 2022, Primary norfloxacin prophylaxis for APASL-defined acute-on-chronic liver failure: a placebo-controlled double-blind randomized trial, Am J Gastroenterol, 10.14309/ajg.0000000000001611

Subramaniyan, 2021, Alcohol-associated liver disease: a review on its pathophysiology, diagnosis and drug therapy, Toxicol Rep, 8, 376, 10.1016/j.toxrep.2021.02.010

Nguyen-Khac, 2011, Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis, N Engl J Med, 365, 1781, 10.1056/NEJMoa1101214

Akriviadis, 2000, Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial, Gastroenterology, 119, 1637, 10.1053/gast.2000.20189

Lebrec, 2010, Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis, Gastroenterology, 138, 1755, 10.1053/j.gastro.2010.01.040

Role, 2015, Of pentoxifylline and steroids for alcoholic hepatitis - has the last word been said?, J Clin Exp Hepatol, 5, 170, 10.1016/j.jceh.2015.06.005

Mathurin, 2013, Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis, JAMA, 310, 1033, 10.1001/jama.2013.276300

Louvet, 2008, Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids, J Hepatol, 48, 465, 10.1016/j.jhep.2007.10.010

Amjad, 2020, A combination of N-acetylcysteine and prednisone has No benefit over prednisone alone in severe alcoholic hepatitis: a retrospective analysis, Dig Dis Sci, 65, 3726, 10.1007/s10620-020-06142-4

Smilkstein, 1988, Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985), N Engl J Med, 319, 1557, 10.1056/NEJM198812153192401

Moreno, 2010, Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial, J Hepatol, 53, 1117, 10.1016/j.jhep.2010.05.030

Gadour, 2021, Meta-analysis and systematic review of primary renal tubular acidosis in patients with autoimmune hepatitis and alcoholic hepatitis, Cureus, 13

Hiremath, 2013, Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a meta-analysis, Indian J Pharmacol, 45, 54, 10.4103/0253-7613.106436

Holt, 1999, Improvement in renal function in hepatorenal syndrome with N-acetylcysteine, Lancet, 353, 294, 10.1016/S0140-6736(05)74933-3

Izzedine, 2009, Endothelin-receptor antagonist/N-acetylcysteine combination in type 1 hepatorenal syndrome, J Hepatol, 50, 1055, 10.1016/j.jhep.2009.02.002

Sen, 2002, Terlipressin-induced vasoconstriction reversed with N-acetylcysteine: a case for combined use in hepatorenal syndrome?, Gastroenterology, 123, 2160, 10.1053/gast.2002.37303

Hamid, 2011, Is histology required for the diagnosis of alcoholic hepatitis? a review of published randomised controlled trials, Gut, 60, A233, 10.1136/gut.2011.239301.492

Forrest, 2021, Letter: the diagnostic and prognostic significance of liver histology in alcoholic hepatitis—authors’ reply, Aliment Pharmacol Ther, 54, 864, 10.1111/apt.16559

Kalambokis, 2007, Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic review, J Hepatol, 47, 284, 10.1016/j.jhep.2007.05.001

Soyer, 2008, Transjugular liver biopsy using ultrasonographic guidance for jugular vein puncture and an automated device for hepatic tissue sampling: a retrospective analysis of 200 consecutive cases, Abdom Imag, 33, 627, 10.1007/s00261-007-9357-3

Esposito, 2008, Role of transjugular liver biopsy in the diagnostic and therapeutic management of patients with severe liver disease, Radiol Med, 113, 1008, 10.1007/s11547-008-0311-4

Arab, 2021, Diagnosis of alcohol-associated hepatitis: when is liver biopsy required?, Clin Liver Dis, 25, 571, 10.1016/j.cld.2021.03.003

Lucey, 2019, Alcohol-associated cirrhosis, Clin Liver Dis, 23, 115, 10.1016/j.cld.2018.09.013

Kim, 2017, Life-sustaining treatment and palliative care in patients with liver cirrhosis - legal, ethical, and practical issues, Clin Mol Hepatol, 23, 115, 10.3350/cmh.2017.0018

Mudumbi, 2018, Palliative care and hospice interventions in decompensated cirrhosis and hepatocellular carcinoma: a rapid review of literature, J Palliat Med, 21, 1177, 10.1089/jpm.2017.0656

Holden, 2020, Palliative care and hospice referrals in patients with decompensated cirrhosis: what factors are important?, J Palliat Med, 23, 1066, 10.1089/jpm.2019.0501

Poonja, 2014, Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management, Clin Gastroenterol Hepatol, 12, 692, 10.1016/j.cgh.2013.08.027

2021

2021